NVO ▲ +2.8% - Novo Nordisk A/S $NVO - NOVO: CHMP RECOMMENDS EU APPROVAL OF FREHEMGO® (DENECIMIG) Novo Nordisk shares rose 2.8% following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve Frehemgo® (denecimig) in the EU. The recommendation moves the company closer to bringing the new treatment to European patients and represents a regulatory milestone for the drug candidate. 17-SEP-2026 10:16 AM ET